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Abstract
Background: Muscle fibrosis characterizes degenerated muscles in muscular dystrophies and in late onset
myopathies. Fibrotic muscles often exhibit thickening of the extracellular matrix (ECM). The molecular regulation of
this process is not fully understood. In oculopharyngeal muscular dystrophy (OPMD), an expansion of an alanine
tract at the N-terminus of poly(A)-binding protein nuclear 1 (PABPN1) causes muscle symptoms. OPMD patient
muscle degeneration initiates after midlife, while at an earlier age carriers of alanine expansion mutant PABPN1
(expPABPN1) are clinically pre-symptomatic. OPMD is characterized by fibrosis in skeletal muscles but the causative
molecular mechanisms are not fully understood.
Methods: We studied the molecular processes that are involved in OPMD pathology using cross-species mRNA
expression profiles in muscles from patients and model systems. We identified significant dysregulation of the ECM
functional group, among which the procollagen C-endopeptidase enhancer 1 gene (PCOLCE) was consistently
down-regulated across species. We investigated PCOLCE subcellular localization in OPMD muscle samples and
OPMD model systems to investigate any functional relevance of PCOLCE down-regulation in this disease.
Results: We found that muscle degeneration in OPMD is associated with PCOLCE down-regulation. In addition to
its known presence at the ECM, we also found PCOLCE within the nucleus of muscle cells. PCOLCE sub-cellular
localization changes during myoblast cell fusion and is disrupted in cells expressing mutant expPABPN1. Our results
show that PCOLCE binds to soluble PABPN1 and co-localizes with aggregated PABPN1 with a preference for the
mutant protein. In muscle biopsies from OPMD patients we find that extracellular PCOLCE is depleted with its
concomitant enrichment within the nuclear compartment.
Conclusions: PCOLCE regulates collagen processing at the ECM. Depletion of extracellular PCOLCE is associated
with the expression of expPABPN1 in OPMD patient muscles. PCOLCE is also localized within the nucleus where it
binds to PABPN1, suggesting that PCOLCE shuttles between the ECM and the nucleus. PCOLCE preferentially binds
to expPABPN1. Nuclear-localized PCOLCE is enriched in muscle cells expressing expPABPN1. We suggest that
nuclear entrapment of PCOLCE and its extracellular depletion represents a novel molecular mechanism in late-onset
muscle fibrosis.
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Background
The extracellular matrix (ECM) plays a key role in regu-
lating homeostasis and tissue repair. Wound healing and
fibrosis are highly regulated by the ECM [1]. The ECM
surrounding skeletal muscle tissue maintains cellular
function and fibre structure, and further provides an en-
vironment for muscle fibre contraction. Defects or defi-
ciencies in molecules that reside in the ECM can cause
skeletal muscle myopathy and muscle fibrosis [2]. Fi-
brotic muscle tissue exhibits an excess accumulation of
collagen and other ECM components [3], leading to ab-
errant muscle fibre function [4]. The role of the ECM in
muscle function has been extensively studied in
Duchene muscular dystrophy (DMD). DMD is caused by
mutations in the gene that encodes Dystrophin, a mech-
anical transducer muscle protein that transmits external
stimuli into the cell. When Dystrophin is mutated, sig-
nals from the ECM are poorly transduced into the cell
[5]. Nevertheless, the molecular mechanisms that are as-
sociated with changes in the ECM in different myop-
athies are not fully understood.
Oculopharyngeal muscular dystrophy (OPMD) is a
late-onset, usually autosomal dominantly inherited my-
opathy [6]. In OPMD muscle weakness is progressive
and initially affects muscles of the eyelid, throat and
proximal limbs. OPMD patients harbour a triplet repeat
expansion mutation in the gene encoding poly(A)-bind-
ing protein nuclear 1 (PABPN1), leading to an expansion
of the poly-alanine (poly-Ala) tract at the N-terminus of
PABPN1 [7]. Alanine expanded PABPN1 (expPABPN1)
is prone to aggregation and forms insoluble inclusions
within the nuclei of skeletal muscle fibres in OPMD pa-
tients [8]. In addition, OPMD muscles contain rimmed
vacuoles, which are a characteristic of fibrotic muscles
[9]. Fibrotic muscles were also reported in a mouse
model of OPMD that over expresses expPABPN1 in
skeletal muscles [10,11]. To date, ECM defects and their
potential contribution to OPMD muscle symptoms have
not been investigated.
Here we report deregulation of the ECM functional
group in OPMD Vastus lateralis (VL) muscles.
Dysrgulation of the ECM was consistent in model sys-
tems for OPMD. We focused on procollagen C-
proteinase enhancer 1 (PCOLCE; PCPE-1) as it was
found to be consistently deregulated in OPMD patients
and in a muscle cell model system of this condition.
PCOLCE is predominantly localised at the ECM, where
it functions as a positive regulator of collagen deposition
[12]. Nuclear-localised PCOLCE co-immunoprecipitates
with soluble expPABPN1 and co-localises with aggre-
gated PABPN1. In both cell and animal model systems
of OPMD that express expPABPN1, PCOLCE retention
in the nucleus was concomitant with reduced accumula-
tion in the ECM. We suggest that nuclear entrapment of
PCOLCE is associated with its extracellular depletion,
and hence represents a novel mechanism by which this
protein is involved in muscle fibrosis.
Methods
Cell culture and collection of muscle biopsies
An ImmortoMouse-derived myoblast cell clone, desig-
nated IM2, was produced as previously described [13],
and used to generate stably transfected clones expressing
either normal Ala10-humanPABPN1-FLAG (Ala10) or
mutant Ala17-humanPABPN1-FLAG (Ala17) [14]. Cells
were maintained in a proliferating medium containing
DMEM (Invitrogen, Carlsbad, CA, USA), supplemented
with 20% foetal calf serum (FCS) (Invitrogen), 0.5%
chicken embryo extract (PAA laboratories, Somerset,
UK), 100 U/ml penicillin/streptomycin, 2 mM L-glutam-
ine and 20 U/ml IFNγ (HyCult Biotech, Uden, The
Netherlands) at 33°C in a humidified 10% CO2-air at-
mosphere. Myoblast fusion was conducted with conflu-
ent cultures maintained in fusion medium consisting of
DMEM containing 5% horse serum without IFNγ and
incubation at 37°C in a humidified 5% CO2-air atmos-
phere for up to 5 days. Details of the generation of the
Ala10 and Ala17 IM2-derived clones used in this study
have been previously described [14].
All human VL muscle biopsies analysed in this study
were collected at Radboud Hospital, Nijmegen, Netherlands
and are listed in Table 1. VL muscle biopsies were collected
using the Bergstrom needle procedure after approval from
the medical ethical committee at Arnhem Nijmegen (CMO
nr.:2005/189). Biopsy sampling from mice was conducted
at Royal Holloway College, University of London, Egham,
Table 1 Clinical description of OPMD patients and
pre-symptomatic carriers contributing to this study
Symptomatic Pre-symptomatic
Age MRC score Gender Age MRC score Gender
49 4 Female 37 ND Female
54 5 Female 37 ND Female
57 4 Female 38 ND Male
59 5 Male 39 ND Female
60 4 Female 39 ND Female
60 4.5 Female 41 ND Female
66 4.5 Male
68 3.5 Male
69 4.5 Female
The age of medical examination and biopsy sampling is indicated. Medical
research conceal (MRC) score is a non-linear clinical measure for muscle
strength. MRC was determined in left and right quadriceps and the average of
both legs is shown. An MRC smaller than 5 indicates clinical muscle weakness.
Clinical investigation was carried out by a single doctor and was performed at
the same day of biopsy sampling. Clinical muscle weakness is not found in
pre-symptomatic and in controls subjects (ND).
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UK, following ethical approval from the Ethical Review
Board at Royal Holloway (University of London) and the
UK government Home Office, under license to Prof G
Dickson (project nr. PPL70/7008: Personal license reference
number – PIL 70/7682).
Protein analysis and detection procedures
Total protein extracts from unfused myoblast and fused
myotube cultures were produced by direct lysis in so-
dium dodecyl sulphate (SDS) loading buffer (50 mM
Tris pH 6.8, 10 mM DTT, 2% SDS, 0.1% bromophenol
blue, 20% glycerol). Samples were resolved by 10% poly-
acrylamide gel electrophoresis (PAGE) under denaturing
conditions followed by Western blot analysis.
Immonoprecipitation of soluble proteins was conducted
with protein extracts from 4-day fused myoblast cultures.
Proteins were extracted with a buffer containing 150 mM
NaCl, 50 mM Tris pH7.5, 0.1% Tween and protease
inhibitor cocktail (Sigma-Aldrich, Saint Louis, Missouri,
USA). FLAG-tagged PABPN1 protein in these extracts
was bound with rabbit-anti FLAG (Sigma-Aldrich) anti-
bodies and precipitated with Protein-A Sepharose
(Sigma-Aldrich). After extensive washing with decreasing
NaCl concentrations (150-0 mM), loading buffer was
added and samples resolved by 10% SDS-PAGE followed
by Western blot analysis.
Western blot analysis was conducted by a transfer of SDS-
PAGE resolved products onto PVDF membranes. Detection
of primary antibodies was conducted after incubation with
horseradish peroxidase (HRP)-conjugated secondary anti-
bodies with the Amersham Hybond ECL chemilumines-
cence detection system (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden).
Histological staining and immunofluorescence analysis
of myotube cultures was performed as previously de-
scribed [14]. Human skeletal muscle cryosections were
generated from biopsy samples of VL muscles from both
healthy controls and OPMD patients after informed con-
sent. Mouse muscle sections were generated from Tibi-
alis anterior (TA) muscles from wild type or A17.1
OPMD model mice [10] at 12, 18 and 26 weeks of age.
Sections were fixed in PBS/3.7% formaldehyde for 30 mi-
nutes followed by permeabilisation with 1% Triton-X100
for 30 min and washing with PBS following antibody in-
cubations as above.
Treatment with 1 M KCl was for 20 minutes and pre-
ceded tissue fixation. Human muscle sections were incu-
bated with 0.3% Sudan Black B (Sigma-Aldrich) for 10 min
to eliminate background from intrinsic autofluorescent
pigments. After completion of antibody staining steps, sam-
ples were overlaid with cover-slips mounted in Vectashield
(Vector, Peterborough, UK) or Vectashield containing
4′-6-diamidino-2-phenylindole (Sigma-Aldrich) at a con-
centration of 3 ng/l. Images were recorded with a Zeiss
Axiovert (model 135TV) fluorescence microscope equipped
with a 100-W mercury arc lamp and a 40x/1.3 NA plan
Apo objective. Single confocal sections were obtained
with a Leica TCS/SP2 confocal microscope system
equipped with a 100x/1.4 NA plan Apo objective.
For histological staining, human specimens were
processed for light microscopic investigation and stained
with haematoxylin-eosin.
Primary antibodies used were: mouse monoclonal
anti-FLAG M2 (Sigma-Aldrich); mouse monoclonal
anti-muscle actin (MSA) (Novocastra, Newcastle
upon Tyne, UK); mouse monoclonal anti-α-Tubulin
(Sigma-Aldrich); mouse anti-ubiquitin, FK2, (AbCam,
Cambridge, UK); rabbit polyclonal anti-Pcolce (AbCam
and Sigma-Aldrich); mouse anti-Dysferlin (Novocastra);
anti-MBNL1 (donated by Dr. T.A. Cooper Baylor College
of Medicine, Houston, USA), Myc-tagged 3 F5 llama
single chain antibody [15], which is recognised with
mouse-anti-Myc clone SE50 (Sigma-Aldrich) at dilutions
1:1000–3000. Alexa 488-, Alexa 430- or Alexa 594- conju-
gated secondary antibodies against primary antibodies were
obtained from Molecular Probes (Invitrogen).
Image quantification was performed with ImageJ appli-
cation (http://rsbweb.nih.gov/ij/).
RNA expression and transcriptome analysis
Bioinformatics analysis of the datasets was as previously de-
scribed and is publically available [16]. Analysis of OPMD-
deregulated ECM pathways was performed with DAVID,
functional annotation clustering tool [17], and statistical
analysis of deregulated pathways was performed with
Globaltest [18]. PCOLCE expression values were obtained
from a list of OPMD-deregulated top tables (p < 0.05), com-
paring expression levels in VL muscles of OPMD and an
age-matched control group [16].
For validation studies reverse transcriptase quantitative-
PCR (RT-qPCR) was performed on mRNA from either TA
muscles of OPMD model and wild type control mice (A17.1
and FVB mice respectively) or murine OPMD model
myotube cultures (wild type IM2 and mutant Ala17). RNA
extraction, cDNA synthesis and RT-qPCR analysis
were performed as previously described [16]. Primers
used in RT-qPCR are listed in Table 2. Statistical analyses
of fold-changes were performed in Excel. Primers used for
individual genes were designed using the Primer3 search
engine at http://www-genome.wi.mit.edu/cgi-bin/primer/
primer3.cgi/ and are listed in Table 2.
Results
Significant ECM deregulation in OPMD
In a recent cross-species study for OPMD we demon-
strated that similar molecular systems are deregulated in
animal models that overexpress expPABPN1 and in
OPMD patients [16]. In addition, similar genome-wide
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transcriptional changes were also found between VL
muscles from OPMD patients and a murine muscle cell
model system where expPABPN1 was expressed in skel-
etal myotube cultures at levels similar to endogenous
Pabpn1 [14]. The ECM pathway in Kyoto Encyclopedia
of Genes and Genomes (KEGG) was consistently
deregulated in OPMD patients and model systems
[14,16]. In KEGG the ECM functional group is only
partly annotated compared with Gene Ontology (GO)
therefore, we performed a Globaltest (GT) analysis of
ECM-associated GO terms. In the GO Cellular Compo-
nent, the basement membrane and Collagen functional
groups were found to be significantly deregulated in
OPMD (Figure 1A, left panel). In the Molecular Func-
tion GO, the ECM-associated Collagen binding and Hep-
arin binding functional groups were also significantly
deregulated in OPMD (Figure 1A, right panel). In the
ECM and in the Collagen functional groups the majority
of the OPMD-dysregulated genes were up-regulated
(72% and 64%, respectively; Figure 1B). This observation
suggests that muscle fibrosis in OPMD is associated with
ECM dysregulation.
In our OPMD cohort, limb-girdle muscles were se-
verely affected [19]. Vastus lateralis muscles from our
patients showed progressive muscle degeneration
(Figure 2). Longitudinal sampling from the same patients
reveals that initially muscle histology was not severely
affected, but after 6 years fat infiltration, rimmed vacu-
oles and ECM thickening was found (Figure 2B). Taken
together, this muscle pathology indicates fibrosis. There-
fore, in this study we focused on the contribution of
ECM dysregulation in muscle fibrosis in OPMD.
Pcolce expression is consistently down-regulated in a
murine myotube culture model of OPMD
Among the dysregulated ECM components, we found a sig-
nificant decrease in the expression of procollagen C-
proteinase enhancer 1 (PCOLCE) in muscle biopsies from
OPMD patients compared with an age-matched control
group (Figure 3A). The expression of PCOLCE in OPMD
correlated with muscle symptoms and decreased between
carriers of expPABPN1 at a pre-symptomatic stage and at a
symptomatic stage (Figure 3A). In order to extend these ob-
servations, Pcolce levels were determined in a mouse model
of OPMD that overexpresses expPABPN1 [10]. As in the
case of OPMD patients, Pcolce mRNA expression in the
OPMD mouse model system was significantly reduced
(Figure 3B). In addition, we also found reduced Pcolce ex-
pression in a murine cellular model for OPMD (Figure 3C).
In this cell culture model system, expPABPN1 is fused to a
Table 2 Primers used for quantitative RT-qPCR
Mouse Pabpn1
Fw CCGGACCACCAACTACAACA
Rv TTGCCCAGGAGCCTGAAG
Mouse Pcolce
Fw CGCTCTCGATTCTACAGTGGTTT
Rv AGGAGAGAGAGGAGGATTATGTGTGAA
Mouse Desmin
Fw CGCTCTGACCCTAAGACAGG
Rv GGAAGCCTCTGGTGTCTCTG
Mouse Hprt
Fw TCCAAGCCGGACCTCACA
Rv CTGAGTCAAGTCTGAAACCTTGGA
FLAG-hPABPN1
Fw CGTCGTGATTAGCGATGATG
Rv TTTTCCAAATCCTCGGCATA
Figure 1 ECM down-regulation in OPMD patients. A. Gene ontology trees of the extracellular region component and binding molecular
function of ECM localized components are significantly deregulated in the human OPMD transcriptome. P-values indicated for each GO-term
were calculated by Global test. Between hyphens the numbers of deregulated genes (left) and the total number of annotated genes per GO-term
(right) are indicated. B. ECM and Collagen encoding genes are predominantly deregulated in OPMD. Histogram shows the percentage of
up-regulated and down-regulated genes in the ECM and Collagen GO categories.
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FLAG epitope and is stably expressed in fused immortalized
skeletal muscle myotube cultures at levels similar to en-
dogenous Pabpn1 [14]. Also, in this cell model we verified a
decrease in Pcolce protein accumulation (Figure 3Cii). Full
length Pcolce (48 kDa) is post-transnationally cleaved gener-
ating a 36 kDa polypeptide, corresponding to a secreted
form of this protein [20]. Extracellular Pcolce enhances pro-
cessing of fibrilar procollagen [12,20,21]. Both the full length
and the cleaved polypeptides were detected in the control
muscle cell culture, but the cleaved polypeptide was differ-
entially expressed between myoblasts and fused myotube
cultures (Figure 3Cii). In cultures expressing the Ala17
expPABPN1 transgene the accumulation of soluble full-
length Pcolce protein decreased and the cleaved polypeptide
was below the level of detection (Figure 3Bii). This suggests
that expPABPN1affects PCOLCE protein accumulation in
muscle cells.
Nuclear Pcolce co-localises in nuclear aggregates and co-
immunoprecipitates with expPABPN1
The presence and location of Pcolce was then deter-
mined in muscle cell cultures using immunolabelling. In
parental un-fused skeletal myoblast cells (IM2) Pcolce
was predominantly present within the nucleus, whereas
in fused myotube cultures a substantial amount was also
detected within the cytoplasm (Figure 4A). This suggests
that Pcolce sub-cellular localisation changes between
upon myoblast differentiation to fused myotubes. In
contrast with control cultures, myotubes expressing hu-
man expPABPN1 (Ala17), Pcolce was predominantly lo-
cated within the nucleus (Figure 4A). Pcolce sub-cellular
localisation in myotube cultures that stably express wild
type PABPN1 (Ala10) was similar to that in parental
IM2 cultures (Figure 4Ai). Taken together, these data in-
dicate that overexpression of mutant expPABPN1 but
not PABPN1 alters PCOLCE sub-cellular localisation.
Furthermore, these observations suggest that expPABPN1
causes accumulation of nuclear PCOLCE.
Formation of expPABPN1 nuclear aggregates is the
hallmark of OPMD. Therefore, we next investigated
whether PCOLCE co-localises with PABPN1 within nu-
clear aggregates. Aggregated PABPN1 forms distinct
fluorescent foci and co-localization with candidate pro-
teins could be determined using intensity distribution
plots [22]. We identified that Pcolce co-localises with
PABPN1 in fluorescent foci in the skeletal myoblast cell
model system (Figure 4Aii). Co-localization was more
pronounced in fluorescent foci formed by expPABPN1
compared with those consisting of wild type PABPN1
(Figure 4Aii). This suggests that PCOLCE binds to nu-
clear PABPN1 and with a preference for expPABPN1
compared to the wild type protein. Analysis by immuno-
precipitation of soluble protein extracts from myotube
cultures with an anti-FLAG antibody that recognises
transgene-derived Ala10- or Ala17- PABPN1-FLAG, re-
vealed that Pcolce co-immunoprecipites with PABPN1
(Figure 4B). Full-length (48 kDa) Pcolce protein co-
immunoprecipitated with both Ala10- and Ala17-
PABPN1-FLAG, but there was a clear enrichment in
binding between Pcolce and mutant Ala17-PABPN1 com-
pared to that with wild type Ala10 PABPN1 (Figure 4B).
These results show that Pcolce binds to soluble PABPN1
but with a higher affinity to expPABPN1.
Pcolce localisation is reduced at the ECM and is retained
in the nucleus in the OPMD mouse model and in OPMD
VL muscles
In order to demonstrate a pathological relevance of the
change in PCOLCE sub-cellular localisation and nuclear
enrichment observed in the skeletal myoblast model sys-
tem of OPMD (Figure 4), we next investigated PCOLCE
localization in cryosections of the Tibialis anterior (TA)
muscle from the A17.1 OPMD mouse model, and in VL
muscles from an OPMD patient. In the mouse model,
the human Ala17 expPABPN1 is overexpressed in skel-
etal muscles with muscle weakness detected in 5–
6 month old animals [10,11]. Aggregated expPABPN1
Figure 2 Transverse cryosections of VL muscle biopsies from an
OPMD patient over a 6 year interval. A) Biopsy taken at the time
of first presentation in the clinic. B) Biopsy of the same muscle as in
(A) taken 6 years later. Sections were stained with haematoxylin-eosin.
Muscle fibrosis is evidenced by fat infiltration (F), vacuole with
basophilic rim (arrowhead) and thickening of the ECM (arrows). Scale
bar equals 100 μm.
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fluorescent foci co-localised with ubiquitin (Figure 5A).
Pcolce co-localisation with expPABPN1 aggregate fluor-
escent foci was found in muscles from 18 and 26-weeks
but not in 12-week old A17.1 mice (Figure 5B). This ob-
servation supports our findings from in vitro analyses,
and suggests that Pcolce is sequestered within nuclear
PABPN1 aggregates after these structures have formed.
In addition to Pcolce co-localisation in PABPN1 nu-
clear aggregates, we observed a concomitant decrease in
the levels of this protein at the ECM in mice aged from
12 to 26 weeks (Figure 6A). In TA sections from wild
type (FVB) mice, Pcolce signal at the ECM did not
change between 12 and 26 weeks (Figure 6A), while in
muscles from A17.1 OPMD model animals a decrease in
extracellular Pcolce signal was evident from week 18 of
age (Figure 6B). In contrast to the decrease in extracellu-
lar Pcolce signal, the amount of nuclear Pcolce remained
high in 18 and 26 weeks old A17.1 muscles (Figure 6B).
This confirms that expression of expPABPN1 induces a
change in PCOLCE sub-cellular localization in muscle. Im-
portantly, the change in Pcolce sub-cellular localization in
the A17.1 OPMD mouse correlated with initiation of muscle
weakness in this model system. This suggests that POLCE
sub- cellular distribution is associated with muscle weakness.
In addition, the extracellular PCOLCE signal in OPMD VL
muscles was reduced compared with its localization in a
healthy control (Figure 7A). Furthermore, in OPMD but not
in the healthy control nuclear PCOLCE showed intense
staining (Figure 7A) whereas the control Dysferlin signal
showed no severe abnormalities in these fibres from the
OPMD patients (Figure 7A).
To confirm that nuclear PCOLCE co-localizes with ag-
gregated PABPN1, muscle sections were treated with
1 M KCl to remove most soluble nuclear proteins. Ag-
gregated nuclear proteins are resistant to KCl treatment
and are present as intense fluorescence foci, whilst sol-
uble proteins are observed as a diffuse signal. However,
it should be noted that the severity of the treatment with
1 M KCl disrupts the morphology of the cell nucleus.
Nevertheless, in the section of OPMD patient muscle
(Figure 7B, lower panel), two nuclei are shown. In one
nucleus the PABPN1 inclusion encompasses most of the
nucleus within which PCOLCE is co-localized with ag-
gregated PABPN1 (Figure 7B, lower panel, arrow). In the
other nucleus, accumulation of aggregated PABPN1 is
far more limited and PCOLCE co-localization is also re-
duced. This suggests that PCOLCE entrapment within
PABPN1 nuclear aggregates is consistent between OPMD
patient and cellular (Figure 4A) and animal (Figure 5) model
systems. In marked contrast to the paucity of nuclear aggre-
gates in OPMD myonuclei (1-5%; [8,23]), the reduction in
extracellular PCOLCE and its nuclear enrichment was uni-
formly distributed throughout the muscle section from the
OPMD patient (Figure 7C). Collectively, our data from the
Figure 3 PCOLCE expression levels are down-regulated in OPMD patients and in a muscle cell model system. A. Plot shows expression
levels of PCOLCE in biopsies from pre-symptomatic muscle that carry expPABPN1 but show no disease symptoms (N = 4) and OPMD symptomatic
samples (N = 5). Fold change was calculated by reference to age-matched controls (N = 19). Only in the symptomatic group PCOLCE is
significantly deregulated (*p < 0.05). B. RT-qPCR analysis of Pcolce mRNA levels in TA muscles of wild-type (FVB) and A17.1 OPMD model mice at
26-weeks of age. Fold change was calculated after normalisation to the Hprt housekeeping gene. Average scores are from 6 mice. Asterisk
indicates significant decline (*p < 0.05). C. Pcolce levels in myotube cultures expressing expPABPN1-FLAG (Ala17) at a level similar to endogenous
Pabpn1. (i) RT-qPCR analysis of Pcolce mRNA expression in myotube cultures of IM2 parental and Ala17 transgene containing cells. Fold change
was calculated after normalisation to the Hprt housekeeping gene mRNA. Variations between fusion efficiencies were eliminated after
normalisation to expression levels from the muscle specific actin (Acta1) gene. Averages are from 3 biological replicates. Asterisk indicates
significant decline (*p < 0.05). (ii) Western blot analysis of soluble protein extracts from unfused (-) and 4-day fused (+) IM2 and Ala17 cultures.
The blot was incubated with anti-Pcolce antibody. Human PABPN1 is detected with an anti-FLAG antibody, the ACTA1 (MSA) protein is a marker
for myotube differentiation and tubulin is used as a loading control.
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OPMD cell and animal model systems combined with that
obtained from patient VL muscle biopsy samples, highlights
a change in the sub-cellular distribution of PCOLCE in
OPMD.
In order to determine whether change in PCOLCE
sub-cellular distribution is a general phenomenon of
muscle wasting, PCOLCE sub-cellular localisation was
studied in VL muscles of patients with DMD, myotonic
dystrophy type 1 (DM1) and Facioscapulohumeral mus-
cular dystrophy (FSHD). Histological analysis of muscle
biopsies from all these conditions revealed widespread
fibrosis and ECM thickening throughout muscle fibres
(Figure 8A). In this same series of sections, PCOLCE
staining was uniformly localized to the ECM in the
DMD and FSHD samples (Figure 8A). A reduction in
PCOLCE at the ECM and enrichment of this protein
within the nucleus was observed in DM1 (Figure 8A). A
quantitative comparison of nuclear PCOLCE across
these 4 muscle disorders demonstrated PCOLCE nuclear
enrichment in OPMD and DM1 compared to DMD and
FSHD (Figure 8B). This suggests that nuclear entrap-
ment of PCOLCE is not a general phenomenon in
muscle degeneration.
Discussion and conclusion
ECM defects are associated with muscle fibrosis of mus-
cular disorders, and are usually detected at a progressed
state of the disease. Muscular dystrophies including
OPMD are characterised by the presence of fibrotic
muscles. Deregulation of the ECM is found in inherited
degenerative muscle diseases such as DMD, FSHD and
α-sarcoglycan deficiency [24-26]. ECM thickening in
DMD patients are associated with significant dysregulation
of collagen and other ECM protein genes [25]. Muscles
from symptomatic patients show ECM thickening that is
typical of fibrotic tissue. Collagen type I and III are major
Figure 4 Co-localisation and co-immunoprecipitation of nuclear Pcolce with expPABPN1 in myotube cultures. A. Pcolce sub-cellular
localisation in myotube cultures. (i) Parental IM2, and those stably expressing Ala17- or Ala10- FLAG-tagged PABPN1were co-stained for Pcolce
and PABPN1. PABPN1 was detected with 3 F5-VHH llama antibody and anti-mouse Alexa 594. Rabbit-anti-Pcolce antibody was detected with
Alexa 488. Nuclei are counterstained with DAPI. Scale bars equal 20 μm. Arrows indicate unfused myoblast cells. (ii) Single confocal microscope
section of myonuclei in Ala17 or Ala10 cell clones. Co-localisation of the two proteins is shown in the merged image. Plots of fluorescence
intensity distribution (measured across the line in the merged image) show co-localisation of Pcolce and PABPN1 in fluorescent foci (arrows).
Representative myonuclei with PABPN1 foci are shown. Scale bars equal 5 μm. B. Immunoprecipitation of PABPN1 in protein extracts from
parental IM2, Ala17- and Ala10- PABPN1-FLAG myotube cultures was performed with rabbit-anti-FLAG antibodies. Immunoblotting was
conducted with mouse-anti FLAG antibody or rabbit anti-Pcolce. IgG HC is used as a loading control.
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components of the ECM in skeletal muscle [27], and in
inherited muscular dystrophies an up-regulation of
collagen-encoding genes is associated with thickening of the
ECM. ECM thickening affects muscle contraction and extra-
cellular signal transduction and increased inflammation [5].
In DMD patients, ECM thickening is associated with up-
regulation of collagen encoding genes [25]. Similar to other
muscle disorders, in OPMD we found significant molecular
dysregulation of ECM-associated genes. Since dysregulation
of ECM encoding genes in different cell types are often
Figure 5 Pcolce protein is sequestered within nuclear aggregates of the mouse OPMD model system. Immunofluorescence staining of TA
muscle sections derived from A17.1 OPMD model mice. (A) PABPN1 aggregates were recognised by the high fluorescence intensity of nuclear
PABPN1 and their co-localisation with ubiquitin (arrows). Scale bars are 20 μm. (B) Co-localisation of Pcolce with PABPN1 was conducted on TA
muscle sections from 12, 18 and 26 week old A17.1 mice. PABPN1 is visualised with 3 F5-VHH and mouse anti-myc antibodies (green), Pcolce or
ubiquitin are visualised with rabbit antibodies and are marked in red. Co-localisation between Pabpn1 and Pcolce is shown in yellow in the
merged image. The nucleus is counterstained with DAPI (blue). Nuclear aggregates are indicated with arrows. Scale bars equal 10 μm.
Immunostaining was performed on sections from 3 mice. Shown are representative images.
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associated with ECM thickening and profibrotic situations
[28], it is highly likely that the transcriptional changes in the
ECM functional group in OPMD are associated with muscle
degeneration.
We identified consistent down-regulation of PCOLCE
in OPMD patient and cellular and mouse model systems
of this condition. In carriers of expPABPN1, down-
regulation was found in symptomatic patients but not at
the pre-symptomatic stage of the disease. This suggests
that the change in PCOLCE expression in muscles is
associated with muscle degeneration. PCOLCE is down-
regulated in OPMD and is found in PABPN1 nuclear
aggregates. Products of dysregulated genes in model
systems expressing expPABPN1 often co-localize with
PABPN1 within nuclear aggregates [16,29]. The mechanism
as to how this occurs is not fully understood. However, it is
possible that a feedback-forward regulatory mechanism
between protein aggregation and mRNA accumulation is
disturbed when aggregates are formed.
The procollagen I peptide is proteolytically processed
to form collagen fibres. Extracellular PCOLCE stimulates
the function of procollagen C-proteinase, thereby lead-
ing to increased cleavage and processing of procollagen
I proteins [21]. Pcolce deficient mice exhibit ECM
thickening, aberrant procollagen peptide processing
and deformed collagen fibril morphology [30]. Taken
together these processes suggest that a reduction in
PCOLCE at the extracellular matrix would diminish colla-
gen fibrillogenesis and hence negatively affect ECM main-
tenance [30]. Of relevance to muscle disorders, Pcolce
down-regulation has been found in Myostatin-knockdown
mice, and was associated with reduced collagen con-
tent and muscle fibrosis [31]. It is therefore likely that
in OPMD a reduced expression of PCOLCE causes
ECM thickening and consequently contributes to muscle
fibrosis.
PCOLCE is a secreted protein. It is synthesized in the
lumen of the ER and is transported to the extracellular
compartment via the Golgi apparatus and associated se-
cretion pathway [12]. In addition to its known extracel-
lular location at the ECM, we found PCOLCE to also be
present within the cell nucleus. We found that PCOLCE
sub-cellular localization is dynamic in muscle cells, and
changed upon myoblast differentiation to fused myotubes.
In degenerated OPMD muscles, a reduction in extracellu-
lar PCOLCE is associated with retention of this protein
within the nucleus. Since PCOLCE protein biosynthesis
is at the secretary Golgi apparatus, this suggests that
PCOLCE may shuttle from the extracellular into the
cell nuclear compartment. However, the mechanism
regulating PCOLCE sub-cellular localization remains
to be investigated.
We found that PABPN1 co-immunoprecipitates with
PCOLCE (Figure 4B). Since PABPN1 is predominantly
localized within the cell nucleus and we found co-
localization of PABPN1 and PCOLCE within this
sub-cellular compartment (Figures 4A, 5 and 7B), we
conclude that PCOLCE binds to nuclear PABPN1 and
consequently is entrapped in PABPN1 aggregates.
Co-localization between PCOLCE and aggregated
PABPN1 was found to be consistent between cellular
and animal model systems of OPMD as well as within
OPMD patient muscle samples. Protein entrapment
within PABPN1 inclusions is a gradual process where
proteins such as ubiquitin or poly(A) polymerase co-
localize with small and intermediate sized aggregates,
whilst others like heat-shock protein 70 (HSP70) are
recruited to large and non-reversible aggregates [22].
Figure 6 Reduction of Pcolce signal at the ECM in the OPMD model mice. (A) Immunofluorescence staining of TA muscle sections of 12-
and 26-week old wild type (FVB) and A17.1 OPMD model mice was conducted with anti-Pcolce antibodies (red). DAPI staining of nuclear DNA
(blue) is merged. Some nuclei with entrapped Pcolce are indicated with arrows. Scale bars are 20 μm. (B) Immunolocalisation of Pcolce in
sections from 12 and 18-week old A17.1 mice was conducted in combination with anti-dysferlin (green), which marks the sarcolemma of skeletal
muscles. Some nuclei with entrapped Pcolce are indicated with arrows. Scale bars are 10 μm. Immunostaining was performed on sections from 3
mice for each genotype. Shown are representative images.
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Since only limited co-localization of PCOLCE and
PABPN1 was found in OPMD nuclei with reduced
amounts of aggregated PABPN1 (Figure 7B), it is likely
that PCOLCE, as in the case of HSP70, is also recruited
to inclusions but not to the intermediate sized PABPN1
aggregated structures.
PABPN1 is a regulator of mRNA processing
[32-35]. A functional role for nuclear PCOLCE is, as
yet, unknown. PCOLCE contains RNA binding motifs
and a role in RNA stabilisation has been suggested
[36]. Here we show that PCOLCE binding to PABPN1
is enriched in cells expressing mutant expPABPN1.
This suggests that PCOLCE binding to PABPN1 is of
relevance to OPMD pathogenesis. It is possible that
due to the alanine expansion in expPABPN1 the dy-
namics of the PCOLCE-PABPN1 complex is reduced
and that this in turn could negatively affect PABPN1
function.
In contrast to the paucity of PABPN1 nuclear aggre-
gate formation in affected myonuclei [8,23], we found a
consistent reduction in ECM-localised PCOLCE levels
across muscle fibres of OPMD patients, and in a mouse
Figure 7 PCOLCE sub-cellular localisation in OPMD and control muscle biopsies. Muscle cryosections were co-stained for PABPN1 (red;
3 F5-VHH) and PCOLCE (green; 3 F5-VHH). Nuclei were counterstained with DAPI (blue). Arrows point to nuclear PCOLCE that colocalizes with
aggregated PABPN1. (A) The sarcolemma is highlighted by staining for dysferilin (purple). Scale bar equals 10 μm. (B) Immunofluorescence after
KCl treatment. Treatment with 1 M KCl disturbs localisation of soluble proteins whilst aggregates remain intact (arrow). Co-localisation between
PABPN1 and PCOLCE is shown in the merged image. Scale bar equals 5 μm. (C) Changes in PCOLCE sub-cellular localisation shown at low
magnification. PABPN1 and DAPI mark nuclei. Scale bar equals 30 μm.
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model of this disease. This consistency suggests that this
feature could be employed as a marker of affected muscles
in OPMD patients. In a skeletal myoblast cell model system
expressing expPABPN1, we observed accumulation of nu-
clear PCOLCE and co-localisation of PCOLCE with aggre-
gated PABPN1. This observation was confirmed in OPMD
patient muscle biopsy samples, where nuclear PCOLCE
accumulation was more prominent compared with that
seen in a healthy control or other muscular dystrophies,
namely DMD and FSHD. As both OPMD and MD1 are
classified as late onset disease conditions whilst DMD starts
within childhood and symptoms in FSHD are typically
observed from around 20 years of age, it is possible
that the change in PCOLCE sub-cellular localisation
may be of greater relevance to late onset muscle disorders.
However, the contribution of dysregulation of PCOLCE
sub-cellular localisation to disease pathophysiology remains
to be demonstrated.
Figure 8 Nuclear localisation of PCOLCE is enriched in OPMD compared to other muscular dystrophies. A. Sub-cellular localisation of
PCOLCE in DMD, FSHD and DM1 patient muscle. Cryosections were stained for PCOLCE and Dysferlin. Dysferlin shows a sarcolemmal localisation.
In DMD and FSHD biopsies there is no clear reduction of PCOLCE at the ECM. In DM1 areas with reduced PCOLCE at the ECM are indicate with
arrows. Scale bar equals 10 μm. B. Accumulation of PCOLCE in myonuclei was quantified using overlap in intensity distribution between DAPI
(blue) and PCOLCE (red). Plots show two nuclei without enrichment with nuclear PCOLCE (i) or with PCOLCE enrichment (ii). Histogram (iii) shows
the quantification of 100 nuclei from FSHD, DMD, DM1 and OPMD muscle biopsies.
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